SGO meeting Tuesday

Here are the top tweets from the SGO meeting on Tuesday!  

Treating the Whole Patient

If no one talks about it, we aren’t treating the WHOLE patient. Break through the barriers. Sexual health is part of our responsibility as female health providers. #SGOmtg #SGOHawaii50 pic.twitter.com/vsotOJjxoZ

— Kristin Koerten (@KMKoerten) March 19, 2019

Patient Perspective on Clinical Trials

Yes- Thank-you Mary for educating us re patients’ concerns. So important for us as we design #clinicaltrials! #sgomtg @gyncsm https://t.co/H9nLSFC2JI

— Bhavana Pothuri (@BPothuri) March 19, 2019

 Maintenance Olaparib

Maintenance Olaparib May Be More Cost-Effective Than Bevacizumab in iBRCA/i-Mutant Ovarian Cancer #SGOMtg https://t.co/Rm4QL3GoD1

— SGO (@SGO_org) March 19, 2019

GAS6 and chemoresistance

#SGOMtg learns increased GAS6 assoc w/ #chemoresistance & lower #PFS in patients w/ high-grade #OvarianCancer

Chemo + anti-GAS6 AVB-500 decreases #tumor burden, tumor & stromal cell viability in mouse #PDX #modelhttps://t.co/7aGWxrQUsR#oncology #immunotherapy #antibody pic.twitter.com/IMZo1s0rrO

— DDNews Online (@DDNewsOnline) March 19, 2019

Immunotherapy

Dendritic cell-based immunotherapy (DCVAC/OvCa) with chemotherapy in patients with platinum-sensitive, relapsed, epithelial ovarian carcinoma: Survival analysis of a phase II, open-label, randomized, multicenter trial (study SOV02). #SGOMtg https://t.co/HZEMOBK9Bj

— SGO (@SGO_org) March 19, 2019

Wonderful distillation of immunotherapy session by @KunleOdunsiMD of @RoswellPark including where research needs to go in future. Biomarkers predicative of response needed! #sgomtg #gyncsm pic.twitter.com/azdssh7opw

— Annie Ellis (@Stigetta) March 19, 2019

Dr. Cibula presents survival analysis of SOV02 Dendritic Cell Vaccine in ovarian cancer #sgomtg #gyncsm pic.twitter.com/Rw7ZwceAWq

— Annie Ellis (@Stigetta) March 19, 2019

Cisplatin/Gemzar/Pembrolizumab

#SGOmtg Cis/gem/pembro tolerable, but no durable response in platinum-R #ovariancancer. Unfortunately another study showing limited efficacy of #checkpointinhibitors in ovarian cancer.… https://t.co/Hd7oUN7Lz9

— Deanna Teoh, M.D., M.S., FACOG, FACS (@DeannaTeoh) March 19, 2019

Next year's meeting is in Toronto. And the gavel has passed to Dr Huh!

Proud & Honored to “pass the gavel” of leadership to
Dr. Warner Huh , 51st President of SGO at #SGOmtg . Welcome Dr Huh -a Courageous Warrior in our Fight to Eradicate GYN Cancer ! pic.twitter.com/UcpNL9dJRU

— Carol Brown (@drcarolbrownMSK) March 19, 2019

Thank you to  @KMKoerten , @Stigetta, @DeannaTeoh , @drcarolbrownMSK , @SGO_org, @DDNewsOnline, @BPothuri for tweeting from the meeting!


Dee
Every Day is a Blessing!

SGO Annual Meeting - Sunday/ Monday

Delayed but here are some important tweets from the SGO meeting on Sunday and Monday.


Risk Reducing Salpingectomy and QOL

.@karenluMD presenting important #QOL data regarding risk-reducing salpingectomy in #BRCA mutant #previvors of #OvarianCancer salpingectomy led to decreased cancer worry, low decision regret, and fewer menopausal symptoms #gyncsm #SGOHawaii50 #SGOMtg pic.twitter.com/CFceeOmORX

— Shannon Westin (@ShannonWestin) March 17, 2019

@karenluMD presents important @SU2C #OvarianCancer Dream Team WISP results re delayed oophorectomy vs risk reducing salpingo-oophorectomy in high risk patients. #SGOmtg #gyncsm @ocrahope @NOCC_National pic.twitter.com/76KvvQNwhn

— Annie Ellis (@Stigetta) March 17, 2019

 Phase 1 Levantinib and weekly taxol in recurrent OC

Amazing early results #SGOHawaii50 https://t.co/fHwMds3fNz

— Stephanie Blank (@StephanieVBlank) March 17, 2019

PARP and ARID1A

Representing @VCUMassey at #SGOHawaii50! So much excitement over #PARP - I’m honored to be part of this innovative project! @temkins @emma pic.twitter.com/QUFcuIlkwM

— Stephanie Sullivan (@StephASullivan) March 17, 2019

JAVELIN  - Avelumab+peg liposomal doxorubicin VS peg liposomal doxorubicin

Phase 3 JAVELIN results at #SGOmtg: failed to meet primary endpoint; no overall signif. improvement in PFS or OS w/avelumab+peg liposomal doxorubicin vs. PLD alone in platinum-res/ref epithelial OC, but trend toward improvement in PD-L1+ tumors. #SGOHawaii50 @MDEdgeTweets

— Sharon Worcester (@SW_MedReporter) March 17, 2019

Phase 2 Pembro and Bev

Dr. Zsiros presents P2 results of pembro combo with bev and cyclophosphamide #sgomtg #gyncsm pic.twitter.com/6W5GZ3Gymp

— Annie Ellis (@Stigetta) March 17, 2019

Minorities and clinical trials

This is unacceptable. “Minority patients continue to suffer the greatest consequences.” How can we get more minorities involved in clinical trials?? We need to act on what we know. #SGO50Hawaii #SGOMtg pic.twitter.com/Cs01Yft18H

— Kristin Koerten (@KMKoerten) March 18, 2019

OC Patient Preferences - maintenance therapy

.@LarissaAMeyerMD presents her important work regarding patient preferences for maintenance therapy in #OvarianCancer - patients trust their doctor’s recommendation! #gyncsm #SGOHawaii50 #SGOMtg pic.twitter.com/bleUKGbten

— Shannon Westin (@ShannonWestin) March 18, 2019

CCNE1 and BRD4 Expression and platinum resistance

⁦@riskaMD2014⁩ presenting our work #SGOMTG #SGOHawaii50 #gyncsm. Representing ⁦@KUMedCenter⁩ ⁦@KUcancercenter⁩! pic.twitter.com/uhg9hvx7ii

— DineoKhabeleMD (@DKhabeleMD) March 18, 2019

 Thank you @KMKoerten , @DKhabeleMD, @ShannonWestin, @Stigetta, @SW_MedReporter, @StephASullivan, @StephanieVBlank for posting from the meeting!


Dee
Every Day is a Blessing! 

SGO Meeting Highlights via Twitter ~ Day One, March 12, 2017

The Society of Gynecologic Oncology (@SGO_org) is holding it's Annual Meeting March 12th -15th, 2017. I'm unable to attend in person, but I will be following hashtag #SGOmtg to catch the latest news and developments. My plan is to compile noteworthy tweets each day of the meeting and share those in a blog post. 

Here are some tweets I found of interest today-  Sunday March 12th.

Hospital readmission metrics are not an ideal measure in ovarian cancer cases #SGOMtg #qualitycare pic.twitter.com/jFl5DFJt9T

— SGO (@SGO_org) March 12, 2017

@SwisherLiz Tumor factors BRCA and RAD51C methylation are also Predictors of response to PARP in #ovariancancer #SGOMtg pic.twitter.com/rh4zKVWanY

— Karen Lu (@karenluMD) March 12, 2017

Managing PARPi toxicities @ShannonWestin #parpi #SGOMtg

— Robert Tyler Hillman (@RTylerHillmanMD) March 12, 2017

@erinstevensmd @RTylerHillmanMD close monitoring. Early intervention to avoid dose interruptions or dose hold. #SGOMtg #gyncsm

— Shannon Westin (@ShannonWestin) March 12, 2017

TY Joanne Rash for great practical info on talking to survivors about sexual health! Imp QoL issue! #SGOMtg pic.twitter.com/iozdutjuol

— Annie Ellis (@Stigetta) March 12, 2017

#SGOMtg Rationale for therapeutic #cervicalcancer vaccine. pic.twitter.com/gJ4tLyTZmI

— Deanna Teoh, M.D. (@DeannaTeoh) March 12, 2017

Immune biology is complex but exciting. Must consider the microenvironment, genetics, microbiome to develop rational combinations. #SGOMtg

— Rebecca Previs (@BeccaPrevisMD) March 12, 2017

So thankful for the advocates, gyn oncs and researchers sharing what they learn via Twitter. 

Dee
Everyday is a Blessing!